Ascent Industries Co. Completes Sale of American Stainless Tubing, Finalizing Transformation to Pure-Play Specialty Chemicals Platform
'The sale of ASTI, our final operating tubular asset, is more than a milestone — it's a defining moment in Ascent's transformation' said Bryan Kitchen, President and Chief Executive Officer of Ascent. 'We are now a pure-play specialty chemicals company, fully aligned with our vision to build a scalable, high-margin chemicals platform poised for sustainable value creation. With this additional capital, we are well-positioned to reinvest in innovation, expand commercial reach, and pursue new growth opportunities that enhance returns for shareholders.'
We are confident that Triple-S will be an excellent steward of ASTI's strong talent and capabilities.
Angle Advisors served as financial advisor and Amundsen Davis, LLC served as legal advisor to Ascent.
About Ascent Industries Co.
Ascent Industries Co. (Nasdaq: ACNT) is a company that engages in the production and distribution of specialty chemicals. For more information about Ascent, please visit its website at www.ascentco.com.
Forward Looking Statements
This press release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements and to review the risks as set forth in more detail in Ascent Industries Co.'s Securities and Exchange Commission filings, including our Annual Report on Form 10-K, which filings are available from the SEC or on our website. Ascent Industries Co. assumes no obligation to update any forward-looking information included in this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Xcel Energy Second Quarter 2025 Earnings Conference Call
MINNEAPOLIS, July 01, 2025--(BUSINESS WIRE)--On Thursday, July 31, 2025, Xcel Energy (NASDAQ: XEL) will host a conference call to review second quarter 2025 financial results. The earnings report will be released prior to the market open on the same date. The call will begin at 9:00 a.m. Central Time. To participate in the conference call, please dial in at least 10 minutes prior to the scheduled start and follow the operator's instructions. You will be asked for the conference password. US Dial-In: 1-866-580-3963International Dial-In: 400-120-0558Conference Password: 5768023 The conference call will be simultaneously webcast and archived on our website at the following location: Under Company, select: Investors If you are unable to participate in the live event, the call will be available for replay through August 5. Replay InformationUS Dial-In: 1-866-583-1035Replay Password: 5768023# About Xcel EnergyXcel Energy (NASDAQ: XEL) provides the energy that powers millions of homes and businesses across eight Western and Midwestern states. Headquartered in Minneapolis, the company is an industry leader in responsibly reducing carbon emissions and producing and delivering clean energy solutions from a variety of renewable sources at competitive prices. For more information, visit or follow us on X and Facebook. View source version on Contacts Financial analysts may call:Roopesh Aggarwal, Vice President - Investor Relations303-571-2855 News media inquiries please call:Xcel Energy Media Relations612-215-5300Internet: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Citi sees upside for Trade Desk into Q2 results, adds on a catalyst watch
-- Citi placed Trade Desk (NASDAQ:TTD) on a 90-day positive catalyst watch, citing signs of stronger ad spending and robust connected TV (CTV) trends ahead of the company's second-quarter earnings report. The brokerage said it came away 'incrementally more positive' on the outlook after meetings at the Cannes Lions advertising conference, suggesting that macro conditions have stabilized since Trade Desk issued Q2 guidance in early May. That improved backdrop, coupled with healthy CTV activity, may lead to results ahead of expectations, Citi said. The firm maintained a Buy rating and a $90 price target on the stock, noting Trade Desk's positioning as a leading independent demand-side platform. While it acknowledged investor concerns over competition from Amazon's DSP, Citi said Trade Desk remains differentiated and the broader programmatic ad market is large enough to support multiple players. Shares trade at roughly 26 times estimated 2026 EBITDA, according to Citi. A beat in Q2 could drive a re-rating back above 30 times, it said. Citi values the stock based on a blend of discounted cash flow, EV/revenue and EV/EBITDA multiples, noting the company's strong topline growth, consistent take rates, and margin profile amid a secular shift of ad dollars from linear TV to CTV. Related articles Citi sees upside for Trade Desk into Q2 results, adds on a catalyst watch Design platform Figma files for U.S. IPO CD&R joins race for BP's $8 billion Castrol unit, Sky News reports Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol 'REVB.' The CUSIP number for the common stock following the reverse stock split will be 76135L705. The reverse stock split is intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company's equity incentive plans. Separately, the Company also announced that it's ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment this month and topline data expected shortly after. For more information on Revelation, please visit Information for Stockholders Upon the effectiveness of the reverse stock split, each sixteen shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share. Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded down to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock. The Company's transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records for the Company's common stock. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connect with the reverse stock split. Continental Stock Transfer & Trust Co. can be reached at (212) 509-4000 or (800)-509-5586. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
